Payment overview · 2025
General Payments
$126,520.91
145 reported records · 14 companies
Healthcare provider profile · identity verified
Thomas-Duythuc To, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · RENO, NV · NPI 1215129044
Verified facts
What the public records show
CMS Open Payments records show Thomas-Duythuc To, MD received $126,520.91 in general payments during 2025 across 145 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 92.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Verquvo.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 819 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 819 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 521 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $117,173.83 | 92.6% | 92 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5,044.32 | 4.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $1,430.00 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $686.68 | 0.5% | 15 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $468.67 | 0.4% | 8 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $464.42 | 0.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $324.21 | 0.3% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$199.79 | 0.2% | 2 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $187.73 | 0.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $167.33 | 0.1% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $139.98 | 0.1% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $100.95 | 0.1% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $73.69 | 0.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $59.31 | 0.1% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $69,378.00 | 24 |
| Consulting Fee | $35,546.50 | 3 |
| Travel and Lodging | $15,717.58 | 34 |
| Food and Beverage | $5,827.43 | 82 |
| Education | $51.40 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $102,437.40 | 75 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $6,474.32 | 5 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $582.76 | 13 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $468.67 | 8 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $464.42 | 6 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $187.73 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $146.95 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $139.98 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $112.73 | 2 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $103.92 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $73.69 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $52.84 | 1 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| OptiCross Normalized: opticross |
Device | Boston Scientific Corporation | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $7.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 819 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 103 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
103 | 35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
819 | 274 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
819 | 274 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
521 | 154 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 994 | 369 |
| Jardiance | Empagliflozin | 819 | 274 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 790 | 275 |
| Metoprolol Succinate | Metoprolol Succinate | 629 | 216 |
| Spironolactone | Spironolactone | 543 | 199 |
| Entresto | Sacubitril/Valsartan | 521 | 154 |
| Losartan Potassium | Losartan Potassium | 515 | 173 |
| Carvedilol | Carvedilol | 403 | 146 |
| Eliquis | Apixaban | 388 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 320 | 113 |
| Metoprolol Tartrate | Metoprolol Tartrate | 254 | 83 |
| Lisinopril | Lisinopril | 251 | 96 |
| Furosemide | Furosemide | 221 | 85 |
| Xarelto | Rivaroxaban | 214 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 201 | 72 |
| Amiodarone Hcl | Amiodarone Hcl | 189 | 62 |
| Valsartan | Valsartan | 176 | 76 |
| Farxiga | Dapagliflozin Propanediol | 164 | 57 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 140 | 59 |
| Potassium Chloride | Potassium Chloride | 116 | 44 |
| Torsemide | Torsemide | 112 | 52 |
| Kerendia | Finerenone | 103 | 35 |
| Nebivolol Hcl | Nebivolol Hcl | 101 | 40 |
| Ezetimibe | Ezetimibe | 100 | 46 |
| Fenofibrate | Fenofibrate | 86 | 34 |
| Repatha Sureclick | Evolocumab | 85 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 33 |
| Praluent Pen | Alirocumab | 69 | 16 |
| Eplerenone | Eplerenone | 60 | 19 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 54 | 17 |
| Simvastatin | Simvastatin | 50 | 19 |
| Verquvo | Vericiguat | 46 | 15 |
| Irbesartan | Irbesartan | 42 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 11 |
| Flecainide Acetate | Flecainide Acetate | 34 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 14 |
| Sotalol | Sotalol Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | 11 |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Nexletol | Bempedoic Acid | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | 11 |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $126,520.91 · 145 records | Bayer Healthcare Pharmaceuticals Inc. | AVVIGO Guidance System, Barostim Neo System, CARDIOMEMS, General - Balloon Catheters, JARDIANCE, Kerendia, LEQVIO, LifeVest, OptiCross, SAPIEN 3 Ultra RESILIA, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, VENASEAL, VERQUVO, WATCHMAN FLX | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error